Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16112789 | 0.89 | ANO1 (0.42) | ALDH1A1CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL16113162 | 0.89 | CYP3A4 (0.39) | ALDH1A1CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL19262355 | 0.89 | ALDH1A1 (0.38) | ALDH1A1CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL18809185 | 0.87 | CYP3A4 (0.36) | CYP3A4CYP2C8 | |
| SCHEMBL18809160 | 0.87 | CYP3A4 (0.38) | CYP3A4CYP2C8KCNH2 | |
| SCHEMBL16133726 | 0.85 | ALDH1A1 (0.38) | ALDH1A1CYP3A4CYP2C8KCNH2 | |
| SCHEMBL17453385 | 0.85 | CYP3A4 (0.40) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL18809303 | 0.85 | CYP3A4 (0.37) | ALDH1A1CYP3A4CYP2C8KCNH2 | |
| SCHEMBL18809671 | 0.84 | CYP3A4 (0.39) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL16133750 | 0.84 | CYP3A4 (0.37) | ALDH1A1CYP3A4CYP2C8KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738653-B2 | Fused furans for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| EP-2970174-B1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | disclosed |